The Zacks Analyst Blog Highlights Microsoft, Amgen, Honeywell International, Booking Holdings and Stryker

For Immediate Release

Chicago, IL – June 15, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. MSFT, Amgen Inc. AMGN, Honeywell International Inc. HON, Booking Holdings Inc. BKNG and Stryker Corp. SYK.

Here are highlights from Tuesday’s Analyst Blog:

Top Research Reports for Microsoft, Amgen and Honeywell

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., Amgen Inc., and Honeywell International Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
 
You can see all of today's research reports here >>>

Microsoft shares have held up better than the broader Tech sector in the ongoing market decline (down -19.6% in the year-to-date period vs. -24.2% decline for the Zacks Tech sector), reflecting the company's entrenched standing in the space. But the stock has nevertheless lagged the broader market as investors reprice the risks associated with a faster growing software player in a rising interest rate environment.

Nevertheless, Microsoft's performance is benefiting from strength in its Azure cloud platform amid accelerated global digital transformation. Teams' user growth is gaining from continuation of remote work and mainstream adoption of hybrid/flexible work models.

Recovery in the advertising and job markets boosted LinkedIn and Search revenues. Solid uptake of new Xbox consoles is aiding the gaming segment performance. The company is witnessing growth in the user base of its different applications including Microsoft 365 suite, Dynamics and Power Platform. Microsoft expects Surface revenues to grow in the mid-teens range, driven by strong demand for premium devices.

(You can read the full research report on Microsoft here >>>)

Amgen shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+2.1% vs. -45.5%) on the back of a robust pipeline of early and late-stage assets. Several phase III readouts are due in 2022. Lumakras, a first-in-class lung cancer treatment, is off to an excellent start while its label expansion studies are progressing rapidly. Amgen boasts a strong biosimilars portfolio with potential new products expected to drive long-term growth.

However, pricing and competitive pressure are impacting many of Amgen's products and franchises. Several of Amgen's marketed drugs are facing increased pricing headwinds. The IRS tax litigation is an overhang on Amgen shares. Also increasing competition for its legacy products is hurting the sales.

(You can read the full research report on Amgen here >>>)

Honeywell shares have performed better than the peer group as well as the broader market during the ongoing market weakness, which reflects the company's operating excellence and the favorable outlook for its key end markets.

The Zacks analyst sees the company to benefit from strength in productivity solutions and services, advanced sensing technologies and gas detection businesses. For 2022, the company expects its organic revenues to increase 4-7% year over year. It is likely to gain from acquisitions made over time.

Also, the company's ability to generate strong cash flows adds to its strength. It rewards shareholders handsomely through dividends and share buybacks.

(You can read the full research report on Honeywell here >>>)

Other noteworthy reports we are featuring today include Booking Holdings Inc. and Stryker Corp.

Why Haven't You Looked at Zacks' Top Stocks?

Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared+40.3%, +48.2%, +67.6%, +94.4%, and+95.3%. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                       

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research